Arcoma

Arcoma PEG

The PEG Ratio (Price/Earnings-to-Growth) of Arcoma (ARCOMA.ST) as of Oct 24, 2026 is 0.56. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 0.25 — a change of 122.25% (higher).

PEG

0.56

YoY

122.25%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Arcoma is 2025 0.56 . PEG Ratio (Price/Earnings-to-Growth) of Arcoma was 2024 0.25 . It decreases by 122.25% higher compared to the previous year.

The Arcoma PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PEG
Date
PEG
Jan 1, 2014
3.11 SEK
Jan 1, 2019
0.43 SEK
Jan 1, 2020
2.08 SEK
Jan 1, 2022
1.49 SEK
Jan 1, 2023
1.11 SEK
Jan 1, 2024
0.25 SEK
Jan 1, 2025
0.56 SEK
The Arcoma PEG history
YEARPEGYoY
0.56+122.25%
0.25-77.06%
1.11-25.82%
1.49-28.23%
2.08+384.25%
0.43-86.17%
3.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

PEG Ratio (Price/Earnings-to-Growth) of Arcoma is 0.56 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Arcoma changed from 0.25 to 0.56, representing a 122.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Arcoma since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Arcoma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Arcoma

All Key Metrics — Arcoma